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Abstract
In this review, we present recent developments 
i n  t h e  p a t h o l o g y  o f  p r o g r e s s i v e 
glomerulosclerosis. Insights are based on 
evidence provided predominantly by us. We also 
describe a novel approach for studying local 
blockades of the renin-angiotensin system (RAS) 
and the cyclooxygenase-dependent pathway, with 
the objective to ameliorate progressive 
glomerulosclerosis. This method involves an in 
vivo imaging system using confocal laser scan 
microscopy.
Introduction
The  r ena l  g lomeru lus ,  an  a r t e r i a l 
microvasculature system, has been studied 
extensively, not only because it is a representative 
unit of physiological ultrafiltration but also in 
order to understand the mechanisms behind 
glomerular diseases, particularly progressive 
glomerulosclerosis, which can lead to “renal 
death.”  The number of patients with chronic 
renal insufficiency who need hemodialysis or 
renal transplantation has been on the rise 
everywhere [1]. In 2003, of more than one million 
patients worldwide, 320,000 were in the United 
States of America and were receiving 
maintenance dialysis [2]. In Japan, the 
corresponding number of such patients was 
275,000 patients. The annual costs for 
maintenance dialysis were calculated to be more 
than 1.2 billion yen in 2007 [3]. It has been 
suggested that glomerular hemodynamic changes 
or glomerular growth responses may trigger the 
development of glomerulosclerosis, irrespective 
of etiology [4,5]. However, the cellular and 
molecular mechanisms behind progressive 
glomerulosclerosis remain unclear. The ultimate 
aim for any nephrologist is to prevent the 
progression of glomerulosclerosis to renal 
insufficiency, and the regression of sclerotic 
lesions in progressive, chronic glomerular 
diseases, such as diabetic nephropathy and IgA 
nephritis [6].
A n i m a l  m o d e l s  f o r  c l a r i f y i n g  t h e 
pathophysiological mechanisms underlying the 
progression of glomerular disease to renal 
insufficiency
We often use the rat as an experimental model, 
due to its suitability for pathophysiological or 
pharmacological research. Certain experimental 
rat  models  mimic irreversible human 
glomerulosclerosis. Of these, the 5/6 ablation 
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model is the most commonly used and the most 
reliable. This model has also yielded the most 
informative results.  For example,  the 
demonstration that glomerular hyperfiltration, 
hyperfusion, hypertension, and hypertrophy are 
a s s o c i a t e d  w i t h  t h e  p r o g r e s s i o n  o f 
glomerulosclerosis [4,5] originates from this 
experimental model. Other experimental models 
of progressive glomerulonephritis, such as the 
accelerated form of anti-glomerular basement 
membrane nephritis, which is characterized by 
destructive or crescentic glomerular lesions, 
differs substantially from human diabetic 
nephropathy and IgA nephropathy. In progressive 
experimental models of glomerulonephritis, a 
gradually accumulating mesangial matrix is 
observed. 
In a previous study, we reported that 
progressive glomerulosclerosis can be induced in 
rats by a 1-shot injection of anti-Thy-1.1 
monoclonal antibody (antithymocyte serum 
[ATS]), followed by unilateral nephrectomy [7]. 
The antibody binds to a specific epitope involved 
in endothelial-mesangial cell contact [8,9]. 
Several advantages of this experimental model 
were highlighted in the analysis of progression 
f a c t o r s  t h a t  l e a d  t o  i r r e v e r s i b l e 
glomerulosclerosis.  As shown in Fig.1, first, the 
course of disease between nephrectomized 
(1-kidney) and sham-operated (2-kidney) groups 
of rats are comparable, at least at the theoretical 
level, since the same amount of nephritogenic 
antibody is bound to each kidney. Second, there is 
a sharp difference in the prognosis of disease 
between the 1-kidney and the 2-kidney model. 
The 1-kidney model is characterized by 
progressive glomerulosclerotic lesions with renal 
insufficiency, while the 2-kidney model is 
fundamentally reversible [10]. Only one 
procedure of unilateral nephrectomy after the 
disease induction resulted in sharply different 
prognosis. Third, the model can be applied to 
different rat strains, including Munich Wistar rats, 
in which many glomeruli are located directly 
under the vicinal surface of the kidney cortex 
[11,12], and transgenic Sprague Dawley rats 
carrying the enhanced green fluorescent protein 
(EGFP) gene [13,14].
Diabetic nephropathy is the most common 
causal disease leading to renal insufficiency. 
Patients need regular hemodialysis treatment or 
renal transplantation. Animal models with the 
physiological and pathological characteristics of 
diabetic nephropathy are important in further 
clarifying the current understanding of the 
pathogenic mechanisms of progression, and to 
Figure 1. Scheme showing the disease courses of the 1-kidney and 2-kidney models (reference 5)
Anti-Thy-1 nephritis was induced in rats by intravenous injection of 0.5 mg of the anti-Thy-1.1 
monoclonal antibody 1-22-3. Thirty minutes after injection, unilateral nephrectomy of the right 
kidney was performed (1-kidney model). In the 2-kidney model, a sham operation was performed 
30 minutes after injection of the same dose of antibody.
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examine the effect of potential renoprotective 
agents. Rat models with chemically induced 
diabetes such as streptozotocin (STZ)-induced 
diabetes and genetic diabetes such as the Zucker 
diabetic fatty rat are widely used for this purpose 
[15,16]. 
Risk factors involved in the progression to 
glomerulosclerosis
The human circulatory system maintains 
homeostasis inside the body by distributing blood 
in a dose-dependent manner, according to oxygen 
and nutrient requirement. Preserving vascular 
function requires a good balance in whole-body 
physiology. This is certainly also true for the 
renal glomerulus, as a representative unit of 
arterial microvasculature. Glomeruli are 
composed of endothelial cells, mesangial cells, 
and mesangial matrices. Upon glomerular 
damage, glomerular function may be impaired 
before effective repair of the glomerular cells and 
matrix components occurs We showed that 
impairment of vascular regeneration is strongly 
associated with the development of progressive 
glomerulosclerosis in the 1-kidney model, 
compared to the 2-kidney model (when induced 
by a 1-shot injection of ATS) [7]. Semi-
quantitative analysis revealed that the capillary 
density and mRNA expression of platelet/
endothelial cell adhesion molecule (PECAM)-1, 
vascular cell adhesion molecule (VCAM)-1, and 
vascular endothelial growth factor (VEGF) in the 
glomeruli, are significantly reduced in the 
1-kidney group on day 14 (an early stage of 
glomerulonephritis), compared to the 2-kidney 
group. On day 84, the 1-kidney group exhibited 
progressive glomerulosclerotic lesions, followed 
by a decrease in capillary density. In contrast, the 
glomerular architecture of the 2-kidney group 
recovered to an almost normal structure.
Using EGFP-positive bone marrow (BM) 
chimeric rats in the same way as described above, 
progressive glomerulosclerosis was induced by a 
1-shot injection of ATS, followed by unilateral 
nephrectomy (1-kidney model) [14]. We 
examined the recruitment of BM-derived cells in 
isolated glomeruli and frozen sections. A confocal 
laser scan microscopic study revealed that BM-
derived PECAM-1+RECA-1+ endothelial cells 
and OX-7+ mesangial cells contribute to structural 
support for the glomerular capillaries during the 
chronic stage of the disease [14].
There is increasing evidence that changes in 
glomerular hemodynamics may promote the 
development of glomerulosclerosis, irrespective 
of etiology [4,5]. Direct and real-time observation 
of the hemodynamic events occurring in the 
microcirculation such as the glomerular capillary 
tuft, were extremely challenging due to 
limitations of the available microscope optics. 
O n e  o b s e r v a t i o n  o f  t h e  g l o m e r u l a r 
microvasculature in the rat was performed using 
hydronephrotic kidneys [17]. However, 
hydronephrosis is accompanied by a marked 
decrease in kidney blood flow [18-20]. To avoid 
non-physiological effects of operative procedure, 
we introduced an intravital real-time confocal 
laser-scanning microscope (CLSM) system, in 
combination with a high-speed video camera and 
fluorescent tracer labeling [21]. At first, we 
confirmed that the destruction of the mesangial 
supporting system of the glomerular vasculature, 
induced by an intravenous injection of ATS, 
resulted in abnormal hemodynamics within the 
limited tufts of glomeruli [21]. Next, the sequence 
of hemodynamic changes within the glomeruli 
was analyzed in the reversible 2-kidney and 
irreversible 1-kidney ATS models [22]. The 
determining point in glomerulosclerosis 
progression occurs between day 7 and day 14 
after disease induction, when disturbances of 
local intraglomerular blood flow persist in the 
1-kidney group. It should be pointed out that 
disturbance of local intraglomerular blood flow, 
which we called “turbulence of glomerular 
hemodynamics,” significantly precedes 
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progressive glomerulosclerosis, observed 84 days 
after disease induction. From the viewpoint of 
hemodynamics, it is well known that turbulent 
flow requires more pressure for a given flow rate 
than laminar flow does [23]. Therefore, it is 
reasonable to consider that disturbances in 
intraglomerular blood flow in the 1-kidney model 
may induce higher shear and hydrostatic stress 
along the glomerular capillary walls in the early 
phase of renal disease, leading to retardation of 
capillary repair and finally, to progressive 
glomerulosclerosis.
Therapeutic strategies to halt progressive 
glomerulosclerosis: a search focusing on local 
delivery of drugs
In clinical situations, drug therapies for 
glomerulonephritis should be provided after the 
nephritic symptoms are diagnosed. Therefore, it 
is important to identify the point that determines 
whether the progression of glomerulosclerosis is 
reversible or irreversible. As described in the 
above section, the turning point from progressive 
g l o m e r u l o n e p h r i t i s  t o  i r r e v e r s i b l e 
glomerulosclerosis was determined to be 7 to 14 
days after disease induction, at a fully established 
stage of glomerular inflammation.
As shown in Fig.2, we focused on developing 
therapeutic approaches that target 3 possible 
mechanisms involved in the progression of 
glomerulosclerosis. First, we targeted BM-
derived stem cells to stimulate recovery from 
Figure 2. Mechanisms involved in the progression of glomerulosclerosis 
Schema of juxtaglomerular apparatus and glomerulus is shown in addition to the key molecules 
regulating the glomerular hemodynamics. AII; angiotensin II, COX-2; cyclooxygenase-2, NO; nitric 
oxide, PG; prostaglandin, ARB; angiotensin II blocker.
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progressive glomerulosclerosis [24]. EGFP– BM 
chimeric rats were infused with BM cells from 
EGFP+ donors on day 7 after induction of the 
1-kidney model of ATS glomerulonephritis. BM 
cell infusion improved renal function and 
glomerular hemodynamics and ameliorated 
histological alterations with reduced glomerular 
infiltration of macrophages, leading to a dramatic 
reduction in mortality: only 2 of 8 untreated rats 
survived 12 weeks after disease induction, while 
5 of 6 BM cell-infused rats survived till the 12th 
week. In the BM cell-infused group, urinary 
protein excretion, serum creatinine, and blood 
urea nitrogen levels were significantly lower than 
in the untreated group from day 8 until 12 weeks 
after disease induction.
RAS-blocking drugs are known to exert 
beneficial effects on the progression of glomerular 
diseases that would otherwise result in renal 
insufficiency [25]. There is also increasing 
evidence that intrarenal RAS within glomeruli 
and interstitial tissues, including renal tubules, is 
not only involved in physiological processes but 
also in pathological conditions, such as vascular 
remodeling, diabetic nephropathy, and 
glomerulosclerosis [26-29]. Therefore, we 
attempted to block intrarenal RAS by using a 
novel approach that applies renal subcapsular 
implantation of a collagen sponge as a means to 
deliver angiotensin II receptor blocker (ARB) or 
direct renin inhibitor (DRI) locally [30,31]. At 
day 7 after induction of the 1-kidney model of 
ATS glomerulonephritis, pellets of type-1 
collagen containing phosphate-buffered saline, 
ARB (Valsartan), angiotensin II, or direct renin 
inhibitor (Aliskiren), were implanted into the 
subrenal capsular pocket. Local ARB or DRI 
treatment significantly reduced proteinuria and 
ameliorated glomerular pathology, including 
glomerular matrix expansion and the sclerotic 
index. In addition, glomerular blood flow levels 
were also significantly improved compared to 
those in the untreated disease group [30,31].
Using STZ-induced diabetic rats, we examined 
the effects of a selective ARB on renal 
hemodynamic changes [32]. The diameters of 
afferent and efferent arterioles, erythrocyte 
velocities within glomeruli, and volume flow in 
the glomerular capillary loops in 4-day diabetes 
mellitus (DM), were significantly higher than in 
control rats, and these increases were even more 
pronounced in 28-day DM. The ratio of the 
diameter of the afferent artery to the diameter of 
the efferent artery in 28-day DM, 1.11, was 
markedly increased when compared to control 
and 4-day DM groups, 1.05 and 1.07, 
respectively, indicating a continuous increase in 
internal glomerular pressure with time. Local 
ARB treatment improved all these measurements 
and significantly decreased proteinuria, while the 
blood glucose level remained unchanged.
Prostaglandins (PGs) modulate renal function, 
including hemodynamics and water and salt 
homeostasis. These eicosanoids are formed by 
cyclooxygenase (COX)-dependent metabolism of 
arachidonic acid. COX-2 is constitutively 
expressed in the macula densa of the 
juxtaglomerular apparatus and in adjacent 
epithelial cells of the cortical thick ascending 
limb of loop of Henle [33]. We examined the 
pharmacological effects of 2 contrast agents (a 
selective COX-2 inhibitor and a prostacyclin 
analogue, PGI2) on the course of the disease in 
the 1-kidney model of ATS glomerulonephritis 
[34]. The local delivery of a COX-2 inhibitor at 
day 7 after disease induction slowed the 
progression of glomerulosclerosis. However, 
local administration of PGI2 induces vasodilation 
and consequent glomerular hyperperfusion. PGI2 
is, therefore, considered a factor inducing a 
vicious circle in progressive glomerulosclerosis. 
These results are consistent with our working 
hypothesis that disturbance of intraglomerular 
microcirculation is a risk factor for progressive 
glomerulosclerosis [35].
Next, we examined the renoprotective effects 
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of drugs with regard to the inflammatory aspects. 
Local delivery of ARB in STZ-induced diabetic 
rats attenuated monocyte/macrophage infiltration 
in the glomeruli and reduced the glomerular 
expression and translation of endothelial nitric 
oxide (NO) synthesis genes [36]. Activation of 
NF-κB, a well-known player in inflammation and 
in the immune response, can be measured as the 
increase in expression of the p65 subunit of NF-
κB. Local ARB treatment induced an apparent 
reduction in nuclear-localized p65 and in the 
intensity of the staining. Furthermore, glomerular 
expression of the breakdown products of 
145/150-kDa spectrin, a specific marker of 
calpain activation, was dramatically increased in 
diabetic rats, while the protein expression 
reverted to normal levels after local ARB 
treatment. These results indicated that ARB acts 
as an anti-inflammatory drug during the early 
phases of STZ-induced diabetic nephropathy. 
The pharmacological effects of local delivery 
of DRI or COX-2 inhibitor in the 1-kidney model 
of ATS were evaluated. Semi-quantitative and 
quantitative analysis of immunohistological 
findings showed that both treatments significantly 
suppressed mesangial matrix expansion and 
improved glomerular sclerotic index compared to 
the diseased control, representing pathological 
expressions of α-SMA and type 1 collagen 
[31,34]. 
Concluding remarks
In this article, we describe state-of-the-art 
strategies for preventing the progression of 
glomerular diseases to renal insufficiency. Local 
delivery of renoprotective agents such as RAS 
and COX-2 inhibitors can be applied to 
successfully control glomerular hemodynamics 
and to attenuate glomerular inflammation. 
Furthermore, we introduced a new imaging 
system, which enables us to observe glomerular 
circulation. As it is widely accepted that “Seeing 
is believing”, this noninvasive diagnostic device 
can contribute to the analysis of glomerular 
function parameters, including hemodynamics 
and permeability, enabling us to objectively 
diagnose the stage of progression, and to examine 
the pharmacological effect of established or 
newly developed drugs. Further work and time 
will be needed to extrapolate our knowledge from 
in vitro, ex vivo, and in vivo experiments to a full 
clarification of pathogenesis and therapy in 
humans.
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